In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains how AI is expanding endpoint selection ...
In part three of her DPHARM interview, Andrea Valente, CEO of uMotif, explains why truly understanding the patient journey ...
In this Q&A, Andrea Valente, CEO of uMotif, discusses what it takes to build genuine trust between patients and sites, why making technology easier to use isn't the same as making patient-site ...
In today's ACT Brief, we examine why defensible trial data depends on traceability and platform ownership, what CGT site ...
In part two of her DPHARM interview, Andrea Valente, CEO of uMotif, explains why the real technology challenge isn't ...
Benchmarking data showed sourcing approach did not reliably predict timeline, quality, or execution performance across 133 ...
In this episode of Beyond Compliance, Otis Johnson, PhD, MPA, founder and principal consultant at Vantix Operations, speaks with Cecilia Xi, PhD, VP of clinical and scientific affairs at Vivalink, ...
Cell and gene therapy access expands into community care settings only when operational coordination, site readiness, and supply chain standardization become first-order priorities equivalent to ...
In today's ACT Brief, we examine what patient-site relationships need most at DPHARM, how platform-based AI scales across ...
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has ...
In today's ACT Brief, we examine why seizure reduction misses what families want from epilepsy trials, how lab coordination ...
Why clinical development’s next AI bottleneck is not the model, but the system around it. “An AI-enabled workflow should identify the downstream implications of a change, propose aligned updates, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results